Liminatus Pharma Warrants
LIMNW
26 hedge funds and large institutions have $400K invested in Liminatus Pharma Warrants in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
4% more funds holding
Funds holding: 25 → 26 (+1)
10.2% less ownership
Funds ownership: 44.33% → 34.12% (-10%)
52% less capital invested
Capital invested by funds: $837K → $400K (-$437K)
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$19K |
| 2 |
GS
GTS Securities
New York
|
+$5.86K |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$1.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$210K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$7.83K |
| 3 |
Jane Street
New York
|
-$491 |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$488 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$338 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| $43 | -$338 | -1,730 | -86% |
|
27
Bank of America
Charlotte,
North Carolina
| $29 | -$20 | -100 | -33% |
|
|
CF
28
Cantor Fitzgerald
New York
| – | -$210K | -875,817 | Closed |
|
LIMNW Hedge Fund Activity: Q3 2025 in Review
26 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma Warrants (LIMNW) for Q3 2025, worth a combined $400K — down 52% from $837K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LIMNW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 7 trimmed.
The largest buyer was Nomura Holdings, opening a new position worth an estimated $19K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $210K sold.
- 26 institutional investors held Liminatus Pharma Warrants (LIMNW) as of Q3 2025, up from 25 in Q2 2025.
- Funds reported $400K of Liminatus Pharma Warrants stock for Q3 2025, down 52% quarter-over-quarter.
- 2 funds opened new Liminatus Pharma Warrants positions in Q3 2025 and 1 closed out, a net change of +1 holder.
- The largest Liminatus Pharma Warrants buyer in Q3 2025 was Nomura Holdings, an estimated $19K added.
- The largest Liminatus Pharma Warrants seller in Q3 2025 was Cantor Fitzgerald, an estimated $210K sold.
Based on aggregated 13F filings for Q3 2025.